The aim of the study is a medico-economic evaluation to estimate a cost differential between three modalities of Intensity-Modulated Radiation Therapy for cancers of the prostate, cervix and anal canal with pelvic lymph node irradiation : treatment with helical Tomotherapy and dynamic arc therapy using two different technologies: RapidArc or VMAT.

Detailed Description

Not Provided

Study Type ICMJE

Interventional

Study Phase

Not Provided

Study Design ICMJE

Intervention Model: Single Group AssignmentMasking: Open Label

Condition ICMJE

Prostate Cancer

Cervical Cancer

Anal Canal Cancers

Intervention ICMJE

Radiation: Intensity-Modulated Radiation Therapy

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ICMJE

Recruiting

Enrollment ICMJE

120

Completion Date

Not Provided

Estimated Primary Completion Date

March 2015 (final data collection date for primary outcome measure)

Eligibility Criteria ICMJE

Inclusion Criteria:

WHO performance index ≤ 2

Age > 18 years

histologically proven carcinoma: Anal canal cancer locally advanced (> 4 cm and / or N1 to N3) under irradiation on pelvic and inguinal lymph nodes with concurrent chemotherapy. The boost with brachytherapy are accepted Prostate cancer with pelvic lymph nodes and radiation or hormone therapy Cervical Cancer under a purely medical treatment involving irradiation on pelvic lymph nodes and primary tumor with concurrent chemotherapy without surgery. The Boost by external radiotherapy or brachytherapy are accepted.

The investigator must ensure that the patient has not expressed its opposition to participate in this study. The signing of a consent form is optional;